NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-01-173,458,571$2.51
$8.68MBuy
Lawrence A. KenyonChief Financial Officer2024-09-265,000$5.69
$28.45kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian247.72%79,313,849$117.38MInsider
Faisal Ghiath Sukhtian174.55%55,884,786$82.71MInsider
Biolexis Pte Ltd79.47%25,443,159$37.66MInsider
Arun Kumar Pillai71.78%22,982,529$34.01MInsider
Pankaj Mohan25.88%8,285,115$12.26MInsider
Syntone Ventures LLC5.33%1,705,438$2.52MInsider
Blackrock Inc3.42%1,093,522$1.62MInstitution
Vanguard Group Inc2.66%852,540$1.26MInstitution
Jeff Evanson2.53%808,459$1.20MInsider
Terry Dagnon2.04%653,058$966.53kInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK2.26%97.74%Net Buying
PEPG76.44%18.64%Net BuyingNet Buying
QNCX11.08%88.92%Net Buying
PRLD49.50%50.50%Net BuyingNet Buying
ICCC13.42%21.29%Net Buying

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 14.20% institutional shareholders, 613.84% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 79.31M shares representing 247.72% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $123.73M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.